Richard H. Chapman

11.6k total citations · 1 hit paper
69 papers, 3.9k citations indexed

About

Richard H. Chapman is a scholar working on Economics and Econometrics, Endocrinology, Diabetes and Metabolism and General Health Professions. According to data from OpenAlex, Richard H. Chapman has authored 69 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Economics and Econometrics, 14 papers in Endocrinology, Diabetes and Metabolism and 11 papers in General Health Professions. Recurrent topics in Richard H. Chapman's work include Health Systems, Economic Evaluations, Quality of Life (30 papers), Medication Adherence and Compliance (10 papers) and Healthcare Policy and Management (10 papers). Richard H. Chapman is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (30 papers), Medication Adherence and Compliance (10 papers) and Healthcare Policy and Management (10 papers). Richard H. Chapman collaborates with scholars based in United States, United Kingdom and Canada. Richard H. Chapman's co-authors include Peter J. Neumann, Patricia W. Stone, Eileen A. Sandberg, Chaim M. Bell, Susan Grandy, Harold Bays, Douglas M. Surgenor, Edward L. Wallace, Steven D. Pearson and Daniel A. Ollendorf and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Annals of Internal Medicine.

In The Last Decade

Richard H. Chapman

68 papers receiving 3.7k citations

Hit Papers

United States Valuation o... 2019 2026 2021 2023 2019 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. United States Valuation of EQ-5D-5L Health States Using an International Protocol
    2019 251 citations Richard H. Chapman et al. Value in Health profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Richard H. Chapman United States 32 1.3k 596 528 528 490 69 3.9k
Robert W. Dubois United States 34 1.0k 0.8× 448 0.8× 712 1.3× 635 1.2× 178 0.4× 169 4.4k
Colin R. Dormuth Canada 35 1.2k 0.9× 547 0.9× 763 1.4× 390 0.7× 470 1.0× 115 4.3k
Maribel Salas United States 20 295 0.2× 555 0.9× 194 0.4× 182 0.3× 440 0.9× 74 2.9k
William M. McClellan United States 54 1.1k 0.8× 1.5k 2.6× 743 1.4× 1.2k 2.2× 176 0.4× 156 8.4k
Roy M. Poses United States 30 333 0.2× 923 1.5× 1.1k 2.0× 551 1.0× 219 0.4× 60 4.0k
Frank A. Sonnenberg United States 20 1.2k 0.9× 843 1.4× 771 1.5× 625 1.2× 62 0.1× 61 4.2k
John D. Seeger United States 40 504 0.4× 802 1.3× 1.1k 2.1× 212 0.4× 80 0.2× 147 5.5k
Ronald L. Pisoni United States 64 1.1k 0.8× 963 1.6× 2.2k 4.1× 803 1.5× 94 0.2× 246 13.6k
Daniel A. Ollendorf United States 34 1.4k 1.1× 508 0.9× 961 1.8× 482 0.9× 880 1.8× 131 6.5k
Laura Plantinga United States 44 708 0.5× 890 1.5× 867 1.6× 900 1.7× 111 0.2× 179 6.4k

Countries citing papers authored by Richard H. Chapman

Since Specialization
Citations

This map shows the geographic impact of Richard H. Chapman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard H. Chapman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard H. Chapman more than expected).

Fields of papers citing papers by Richard H. Chapman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard H. Chapman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard H. Chapman. The network helps show where Richard H. Chapman may publish in the future.

Co-authorship network of co-authors of Richard H. Chapman

This figure shows the co-authorship network connecting the top 25 collaborators of Richard H. Chapman. A scholar is included among the top collaborators of Richard H. Chapman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard H. Chapman. Richard H. Chapman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Thomas, Simu K., et al.. (2025). HTA Evidence in Rare Diseases: Just Rare or Also Special?. PharmacoEconomics. 43(11). 1271–1279. 1 indexed citations
2.
3.
dosReis, Susan, et al.. (2022). Preferences for Treatments for Major Depressive Disorder: Formative Qualitative Research Using the Patient Experience. Patient. 16(1). 57–66. 3 indexed citations
4.
Chapman, Richard H., Varun Kumar, Melanie D. Whittington, & Steven D. Pearson. (2021). Does Cost-Effectiveness Analysis Overvalue Potential Cures? Exploring Alternative Methods for Applying a “Shared Savings” Approach to Cost Offsets. Value in Health. 24(6). 839–845. 6 indexed citations
5.
Counts, Nathaniel Z., et al.. (2020). Modeling Medicaid and Medicare Savings from Reduced Poverty and Disability to Promote Investment in Mental Health and Substance Use Interventions in the USA. Applied Health Economics and Health Policy. 18(5). 601–604. 1 indexed citations
6.
Thokala, Praveen, et al.. (2020). Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US. Cost Effectiveness and Resource Allocation. 18(1). 41–41. 23 indexed citations
7.
Thokala, Praveen, Matt Stevenson, Varun Kumar, et al.. (2019). PRO15 COST-EFFECTIVENESS OF NUSINERSEN AND ONASEMNOGENE ABEPARVOVEC FOR INFANTILE-ONSET SPINAL MUSCULAR ATROPHY (TYPE I SMA) IN THE US. Value in Health. 22. S337–S338. 3 indexed citations
8.
Zimmermann, Marita, Elizabeth Brouwer, Jeffrey A. Tice, et al.. (2018). Disease-Modifying Therapies for Relapsing–Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis. CNS Drugs. 32(12). 1145–1157. 35 indexed citations
9.
Carlson, Josh J., Gregory F. Guzauskas, Richard H. Chapman, et al.. (2017). Cost-effectiveness of Drugs to Treat Relapsed/Refractory Multiple Myeloma in the United States. Journal of Managed Care & Specialty Pharmacy. 24(1). 29–38. 33 indexed citations
10.
Sandhu, Alexander T., Daniel A. Ollendorf, Richard H. Chapman, Steven D. Pearson, & Paul A. Heidenreich. (2016). Cost-Effectiveness of Sacubitril–Valsartan in Patients With Heart Failure With Reduced Ejection Fraction. Annals of Internal Medicine. 165(10). 681–689. 50 indexed citations
11.
Whittington, Melanie D., R. Brett McQueen, Daniel A. Ollendorf, et al.. (2016). Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis. Annals of Allergy Asthma & Immunology. 118(2). 220–225. 64 indexed citations
12.
Pelletier, E.M., Manjiri Pawaskar, & Richard H. Chapman. (2012). PDB51 Medication Adherence and Medical Costs Associated With Exenatide Bid Versus Liraglutide: A Retrospective Database Analysis. Value in Health. 15(4). A179–A180. 1 indexed citations
13.
14.
Chapman, Richard H., Allison Petrilla, Joshua S. Benner, J. Sanford Schwartz, & Simon Tang. (2008). Predictors of Adherence to Concomitant Antihypertensive and Lipid-Lowering Medications in Older Adults. Drugs & Aging. 25(10). 885–892. 89 indexed citations
15.
16.
Neumann, Peter J., Allison B. Rosen, Dan Greenberg, et al.. (2005). Can We Better Prioritize Resources for Cost-Utility Research?. Medical Decision Making. 25(4). 429–436. 34 indexed citations
17.
Chapman, Richard H.. (2005). Predictors of Adherence With Antihypertensive and Lipid-Lowering Therapy. Archives of Internal Medicine. 165(10). 1147–1147. 407 indexed citations
18.
Jennings, Garry, et al.. (2002). Integrating cost-effectiveness evidence into clinical practice guidelines in Australia for acute myocardial infarction. The European Journal of Health Economics. 3(1). 26–39. 9 indexed citations
19.
Bell, Chaim M., Richard H. Chapman, Patricia W. Stone, Eileen A. Sandberg, & Peter J. Neumann. (2001). An Off-the-Shelf Help List. Medical Decision Making. 21(4). 288–294. 76 indexed citations
20.
Earle, Craig C., Richard H. Chapman, Chaim M. Bell, et al.. (2000). Systematic Overview of Cost-Utility Assessments in Oncology. Journal of Clinical Oncology. 18(18). 3302–3317. 251 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Robert W. Dubois Breakdown of academic impact, for papers by Colin R. Dormuth Breakdown of academic impact, for papers by Maribel Salas Breakdown of academic impact, for papers by William M. McClellan Breakdown of academic impact, for papers by Roy M. Poses Breakdown of academic impact, for papers by Frank A. Sonnenberg Breakdown of academic impact, for papers by John D. Seeger Breakdown of academic impact, for papers by Ronald L. Pisoni Breakdown of academic impact, for papers by Daniel A. Ollendorf Breakdown of academic impact, for papers by Laura Plantinga
Rankless by CCL
2026